Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 4/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26151941 | 0.89 | GSK3B (0.38) | GSK3BGSK3AIDO1MAPTATR | |
| SCHEMBL30418690 | 0.89 | CDK9 (0.38) | CDK9CCNT1GSK3BGSK3AIDO1 | |
| SCHEMBL30445285 | 0.89 | GSK3B (0.38) | GSK3BGSK3AIDO1MAPTATR | |
| SCHEMBL26152085 | 0.89 | CDK9 (0.38) | CDK9CCNT1GSK3BGSK3AIDO1 | |
| SCHEMBL31058902 | 0.89 | CDK9 (0.38) | CDK9CCNT1GSK3BGSK3AIDO1 | |
| SCHEMBL31058907 | 0.88 | CDK9 (0.36) | CDK9CCNT1ATRSCN10ARORC | |
| SCHEMBL26152168 | 0.88 | CDK9 (0.36) | CDK9CCNT1ATRSCN10ARORC | |
| SCHEMBL30417617 | 0.88 | CDK9 (0.36) | CDK9CCNT1ATRSCN10ARORC | |
| SCHEMBL25180704 | 0.88 | GSK3B (0.38) | GSK3BGSK3AIDO1MAPTSCN10A | |
| SCHEMBL30444878 | 0.87 | GSK3B (0.36) | CDK9CCNT1GSK3BGSK3AIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4405344-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | Xenon Pharmaceuticals Inc. (CA) | 2024-07-31 | — | — | EP | disclosed |
| CN-118251389-A | Pyridyl derivatives as sodium channel activators | 泽农医药公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-05-18 | — | — | US | disclosed |
| WO-2023049369-A2 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129044-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | CDK9 2783/4885CCNT1 2930/4885GSK3B 249/4885 |
| US-20230150972-A1 | PYRIDINYL DERIVATIVES AS SODIUM CHANNEL ACTIVATORS | SCN1B, SCN1A, SCN2B | CDK9 2783/4885CCNT1 2930/4885GSK3B 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.